Page last updated: 2024-09-04

torcetrapib and Cardiovascular Diseases

torcetrapib has been researched along with Cardiovascular Diseases in 56 studies

Research

Studies (56)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	31 (55.36)	29.6817
2010's	24 (42.86)	24.3611
2020's	1 (1.79)	2.80

Authors

Authors	Studies
Bis, JC; Charoen, P; Chaturvedi, N; Drenos, F; Finan, C; Franceschini, N; Gaunt, TR; Giambartolomei, C; Gordillo-Marañón, M; Hingorani, AD; Hughes, AD; Hunt, NB; Kivimaki, M; Lawlor, DA; Mook-Kanamori, DO; O'Donnell, CJ; Papacosta, O; Price, JF; Schmidt, AF; Sofat, R; Wannamethee, G; Wong, A; Zwierzyna, M	1
Corsini, A; Macchi, C; Matsuzawa, Y; Ruscica, M; Sirtori, CR; Yamashita, S	1
Taylor, J	1
Sloop, GD; St Cyr, JA; Weidman, JJ	1
Barter, PJ; Kastelein, JJ; Nicholls, SJ; Rye, KA	1
Boekholdt, SM; Hovingh, GK; Ray, KK	1
Di Bartolo, B; Duong, M; Nicholls, SJ; Takata, K	1
Hegele, RA; Joy, TR	1
Krumholz, HM; Lee, TH	1
Jukema, JW; Rensen, PC	1
Neeli, H; Rader, DJ	1
Lange, RA; Lindsey, ML	1
Gore, MO; McGuire, DK	1
Burnier, M; Vogt, B	1
Chen, C; Cheung, WM; Connelly, MA; Cools, F; Damiano, BP; Demarest, KT; Gallacher, DJ; Giardino, EC; Huang, Z; Kuo, GH; Parry, TJ; Sarich, TC; Van der Linde, H	1
Rosenson, RS	1
von Eckardstein, A	1
Weber, C	1
Miura, S; Saku, K	1
Hausenloy, DJ; Opie, L; Yellon, DM	1
Leança, CC; Nakandakare, ER; Passarelli, M; Quintão, EC	1
Niesor, EJ	1
Grammer, TB; Kleber, ME; März, W	1
Duffy, J; Fisher, T; Forrest, MJ; Hubbard, BK; Johns, DG	1
Nicholls, SJ	1
Ghosh, RK; Ghosh, SM	1
Shinkai, H	1
Deanfield, J; Kastelein, J; Landmesser, U; Lüscher, TF; von Eckardstein, A	1
Kathiresan, S	1
Frikke-Schmidt, R; Johannsen, TH; Nordestgaard, BG; Schou, J; Tybjærg-Hansen, A	1
Brewer, HB	1
Bonnette, P; Durham, LK; Freeman, TB; Lanzetti, A; Lira, ME; Lloyd, DB; Milos, PM; Preston, GM; Qiu, X; Sugarman, E; Thompson, JF; Wood, LS	1
Barter, PJ; Kastelein, JJ	1
Tall, AR; Wang, N; Yvan-Charvet, L	1
Ansell, B; Hobbs, FD	1
Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM	1
Hall, JE; Jones, DW	1
Hampton, T	1
Merrick, GS; Moyad, MA	1
Wadman, M	1
Barter, PJ; Brewer, B; Buhr, KA; Caulfield, M; Eriksson, M; Fisher, MR; Grundy, SM; Kastelein, JJ; Komajda, M; Lopez-Sendon, J; Mosca, L; Revkin, JH; Shear, CL; Tall, AR; Tardif, JC; Waters, DD	1
Rader, DJ	1
Alvan, G; Hedenmalm, K; Melander, H	1
Duriez, P	1
Levy, Y	1
Jackson, G	1
Doggrell, SA	1
Heinecke, JW; Oram, JF	1
Olsson, AG	1
Chapman, MJ; Guérin, M; Kontush, A	1
Lackner, KJ	1
Cohn, LJ	1
Dullaart, RP; Kobold, AC; van Tol, A	1
Byrne, CD; Wild, S	1

Reviews

18 review(s) available for torcetrapib and Cardiovascular Diseases

Article	Year
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature communications, 2021, 09-24, Volume: 12, Issue:1 Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Humans; Mendelian Randomization Analysis; Oxazolidinones; Quinolines; Sulfhydryl Compounds	2021
Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. Atherosclerosis, 2018, Volume: 278 Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Lignans; Lipoproteins, HDL; Lipoproteins, VLDL; Oxazolidinones; Probucol; Quinolines; Sulfhydryl Compounds; Triglycerides	2018
CETP Inhibition in CVD Prevention: an Actual Appraisal. Current cardiology reports, 2016, Volume: 18, Issue:5 Topics: Animals; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clinical Trials as Topic; Disease Models, Animal; Evidence-Based Medicine; Humans; Quinolines; Treatment Outcome	2016
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines	2008
Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. Current cardiology reports, 2009, Volume: 11, Issue:4 Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Quinolines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2009
Aldosterone and cardiovascular risk. Current hypertension reports, 2009, Volume: 11, Issue:6 Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Humans; Hyperaldosteronism; Kidney Diseases; Metabolic Syndrome; Obesity; Quinolines	2009
Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target? Expert review of cardiovascular therapy, 2010, Volume: 8, Issue:3 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Quinolines; Risk Assessment; Treatment Failure	2010
[HDL: the yin-yang of cardiovascular disease]. Arquivos brasileiros de endocrinologia e metabologia, 2010, Volume: 54, Issue:9 Topics: Anticholesteremic Agents; Biological Transport; Cardiovascular Diseases; Cholesterol, HDL; Humans; Quinolines; Yin-Yang	2010
Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Current opinion in lipidology, 2011, Volume: 22, Issue:4 Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Humans; Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds	2011
[High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning]. MMW Fortschritte der Medizin, 2010, Jul-01, Volume: 152 Suppl 2 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, Fat-Restricted; Exercise; Humans; Lipase; Lipoproteins, HDL; Liver; Oxidative Stress; Phosphatidylcholine-Sterol O-Acyltransferase; Phospholipid Transfer Proteins; Quinolines; Triglycerides	2010
On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs, 2012, Mar-05, Volume: 72, Issue:4 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Quinolines; Risk Factors; Structure-Activity Relationship	2012
Evacetrapib. Current cardiology reports, 2012, Volume: 14, Issue:3 Topics: Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines	2012
Current status of CETP inhibitors in the treatment of hyperlipidemia: an update. Current clinical pharmacology, 2012, Volume: 7, Issue:2 Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Hyperlipidemias; Oxazolidinones; Quinolines; Risk Factors; Sulfhydryl Compounds	2012
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vascular health and risk management, 2012, Volume: 8 Topics: Amides; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Esters; Humans; Hypolipidemic Agents; Oxazolidinones; Quinolines; Sulfhydryl Compounds; Treatment Outcome	2012
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. Journal of the American College of Cardiology, 2006, Feb-07, Volume: 47, Issue:3 Topics: Amides; Animals; Atherosclerosis; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Esters; Glycoproteins; Humans; Quinolines; Risk Factors; Sulfhydryl Compounds; Vaccines	2006
The potential for CETP inhibition to reduce cardiovascular disease risk. Current medical research and opinion, 2006, Volume: 22, Issue:12 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines; Risk Factors; Vaccination	2006
World Hypertension Day 2007. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5 Topics: Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Global Health; Humans; Hypertension; Quinolines; Risk Factors	2007
Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:6 Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Dyslipidemias; Humans; Hypertension; Quinolines	2008

Trials

4 trial(s) available for torcetrapib and Cardiovascular Diseases

Article	Year
Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. The Journal of biological chemistry, 2005, Apr-15, Volume: 280, Issue:15 Topics: Adult; Aged; Cardiovascular Diseases; Carrier Proteins; Cell Line; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Crystallography, X-Ray; DNA, Complementary; Female; Genome, Human; Glutamine; Glycoproteins; Humans; Inhibitory Concentration 50; Lipoproteins, HDL; Male; Middle Aged; Models, Molecular; Mutation, Missense; Polymorphism, Single Nucleotide; Proline; Protein Binding; Protein Conformation; Quinolines; Transcription, Genetic	2005
Effect of torcetrapib on the progression of coronary atherosclerosis. The New England journal of medicine, 2007, Mar-29, Volume: 356, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional	2007
Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mortality; Pyrroles; Quinolines	2007
CETP inhibition. Lancet (London, England), 2007, Dec-08, Volume: 370, Issue:9603 Topics: Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Quinolines	2007

Other Studies

34 other study(ies) available for torcetrapib and Cardiovascular Diseases

Article	Year
CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit. European heart journal, 2013, Volume: 34, Issue:16 Topics: Amides; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Fibric Acids; Humans; Hypolipidemic Agents; Niacin; Quinolines; Sulfhydryl Compounds	2013
Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity? Therapeutic advances in cardiovascular disease, 2015, Volume: 9, Issue:2 Topics: Amides; Anticholesteremic Agents; Blood Pressure; Blood Viscosity; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Erythrocyte Aggregation; Esters; Humans; Quinolines; Sulfhydryl Compounds; Treatment Failure	2015
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case. Circulation, 2015, Aug-04, Volume: 132, Issue:5 Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome	2015
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief? Circulation, 2015, Aug-04, Volume: 132, Issue:5 Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome	2015
The failure of torcetrapib: what have we learned? British journal of pharmacology, 2008, Volume: 154, Issue:7 Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Humans; Hyperaldosteronism; Oxazolidinones; Quinolines	2008
Redefining quality--implications of recent clinical trials. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Quality of Health Care; Quinolines; Risk Factors	2008
[Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders]. Nederlands tijdschrift voor geneeskunde, 2008, May-10, Volume: 152, Issue:19 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Humans; Hypercholesterolemia; Patient Selection; Quinolines; Randomized Controlled Trials as Topic; Risk Factors; Water-Electrolyte Balance	2008
HDL-cholesterol levels and cardiovascular risk: acCETPing the context. European heart journal, 2008, Volume: 29, Issue:22 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Male; Pharmacogenetics; Quinolines	2008
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:5 Topics: Administration, Oral; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Endothelium, Vascular; Injections, Intravenous; Male; Molecular Structure; Quinolines; Rabbits; Vasodilation	2010
Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:1 Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds	2010
Obstacles and options in the quest for drug candidates against vascular disease. Thrombosis and haemostasis, 2010, Volume: 104, Issue:1 Topics: Aging; Animals; Anticoagulants; Cardiovascular Diseases; CCR5 Receptor Antagonists; Clinical Trials as Topic; Combined Modality Therapy; Contraindications; Drug Design; Humans; Metabolic Diseases; Quinolines; Thiazolidinediones	2010
Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors? Journal of hypertension, 2010, Volume: 28, Issue:8 Topics: Amides; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Esters; Humans; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds	2010
Dissociating HDL cholesterol from cardiovascular risk. Lancet (London, England), 2010, Jul-31, Volume: 376, Issue:9738 Topics: Amides; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Predictive Value of Tests; Primary Prevention; Quinolines; Risk Assessment; Risk Factors; Secondary Prevention; Sulfhydryl Compounds	2010
Trial watch: hope renewed for strategy to raise HDL cholesterol. Nature reviews. Drug discovery, 2011, Volume: 10, Issue:1 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Dyslipidemias; Humans; Oxazolidinones; Quinolines; Risk Factors	2011
Learning lessons from Pfizer's $800 million failure. Nature reviews. Drug discovery, 2011, Volume: 10, Issue:3 Topics: Amides; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Industry; Esters; Humans; Quinolines; Sulfhydryl Compounds	2011
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. European heart journal, 2012, Volume: 33, Issue:14 Topics: Acute Coronary Syndrome; Amides; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Early Termination of Clinical Trials; Esters; Humans; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds	2012
Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trials. Journal of the American College of Cardiology, 2012, Nov-13, Volume: 60, Issue:20 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Female; Humans; Male; Myocardial Ischemia; Quinolines	2012
Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. Journal of the American College of Cardiology, 2012, Nov-13, Volume: 60, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cohort Studies; Female; Genetic Variation; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Quinolines; Risk Factors; Young Adult	2012
High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:3 Topics: Animals; Arteriosclerosis; Biological Transport; Cardiovascular Diseases; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Enzyme Inhibitors; Glycoproteins; Humans; Lipoproteins, HDL; Liver; Macrophages; Mice; Mice, Transgenic; Oxidation-Reduction; Quinolines; Rabbits; Risk Factors	2004
The failure of torcetrapib: was it the molecule or the mechanism? Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:2 Topics: Angina Pectoris; Animals; Anticholesteremic Agents; Atorvastatin; Cardiac Output, Low; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Mice; Myocardial Revascularization; Pyrroles; Quinolines; Rabbits; Treatment Failure	2007
New clues to HDL's benefits revealed. JAMA, 2007, Apr-11, Volume: 297, Issue:14 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Humans; Proteomics; Quinolines	2007
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part VI--The recent rise and fall of the HDL-boosting drug torceptrapib. Urologic nursing, 2007, Volume: 27, Issue:2 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Drug Industry; Exercise Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Patient Education as Topic; Quinolines; Risk Reduction Behavior; Smoking Cessation; Stress, Psychological; United States; Urologic Diseases; Weight Loss	2007
Man on a mission. Nature, 2007, May-31, Volume: 447, Issue:7144 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; History, 21st Century; Humans; Lactones; Quinolines; Rosiglitazone; Sulfones; Thiazolidinediones	2007
Illuminating HDL--is it still a viable therapeutic target? The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines; Up-Regulation	2007
The conscientious judgement of a DSMB--statistical stopping rules re-examined. European journal of clinical pharmacology, 2008, Volume: 64, Issue:1 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Data Interpretation, Statistical; Decision Making; Humans; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment	2008
High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench. Cardiovascular research, 2008, Mar-01, Volume: 77, Issue:4 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Quinolines; Treatment Outcome	2008
Torcetrapib: when global risk reduction goes 'off target'. International journal of clinical practice, 2008, Volume: 62, Issue:2 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Humans; Quinolines; Risk Reduction Behavior	2008
The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Pyrroles; Quinolines; Research Design	2008
When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Current atherosclerosis reports, 2007, Volume: 9, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Liver; Quinolines	2007
Will CETP inhibition survive the demise of torcetrapib? Current atherosclerosis reports, 2008, Volume: 10, Issue:2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Quinolines; Risk Assessment; Risk Factors; Treatment Failure	2008
Torcetrapib and coronary events. The New England journal of medicine, 2008, Apr-24, Volume: 358, Issue:17 Topics: Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Heterozygote; Humans; Quinolines; Treatment Failure	2008
Torcetrapib and coronary events. The New England journal of medicine, 2008, Apr-24, Volume: 358, Issue:17 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines; Treatment Failure	2008
Torcetrapib and coronary events. The New England journal of medicine, 2008, Apr-24, Volume: 358, Issue:17 Topics: Aldosterone; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Female; Humans; Linear Models; Male; Middle Aged; Quinolines	2008
Time to rethink high-density lipoprotein? Heart (British Cardiac Society), 2008, Volume: 94, Issue:6 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Humans; Insulin Resistance; Lipoproteins, HDL; Quinolines; Risk Reduction Behavior	2008